Search results
Is the AI bubble about to burst?
The Independent· 6 days agoThe US chip manufacturer has had more than $550bn (£433bn) wiped from its value since the sellers got to work and blew the top off its Thursday peak. To...
AstraZeneca still a buy for one broker despite mixed Imfinzi data
Proactive Financial News· 6 days agoAstraZeneca PLC (LSE:AZN) has put out mixed data for the Phase III trials of its immuno-oncology...
AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung...
Benzinga via Yahoo Finance UK· 6 days agoOn Tuesday, AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADJUVANT BR.31 Phase 3...
London midday: Stocks fall as Rolls-Royce, Melrose hit by Airbus warning
ShareCast· 6 days agoLondon stocks had fallen into the red by midday on Tuesday, with Rolls-Royce and Melrose pacing the...
TOP NEWS: AstraZeneca details mixed findings from cancer drug trials
Morningstar· 6 days agoShares in AstraZeneca rose 0.6% to 12,548.00 pence on Tuesday morning. The Cambridge-based pharmaceutical company said Imfinzi met both its primary and secondary aims in a trial on sufferers of bladder cancer.
Health Care Roundup: Market Talk
The Wall Street Journal· 6 days agoFind insight on Rigel Pharmaceuticals, AstraZeneca, Merck KGaA and more in the latest Market Talks covering the Health Care sector.
LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake
Morningstar· 6 days ago"One question that everyone asks is whether last week's good news marked the finale of the Nvidia's surge to the top, and if the past three-day selloff is the beginning of a sharper downside ...
AstraZeneca posts mixed results from recent Imfinzi trials
ShareCast· 6 days agoAstraZeneca announced contrasting results from two phase three trials involving its immunotherapy...
AstraZeneca's Imfinzi fails in late-stage trial to treat certain type of lung cancer
Reuters· 6 days agoAstraZeneca said on Tuesday its blockbuster cancer drug, Imfinzi, failed to improve disease-free survival in a late-stage trial to treat a type of early-stage lung cancer.
London pre-open: Stocks to edge up after mixed US session
ShareCast· 6 days agoLondon stocks were set to nudge up at the open on Tuesday following a mixed close on Wall Street.
